TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07723963: A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of JZP926 in Participants Aged 10 Years and Older for the Treatment of Juvenile Myoclonic Epilepsy

Sponsor: Jazz Pharmaceuticals · Phase: PHASE2/PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 260 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$13,017,400

Rescue Site Savings

+$8,615,152

Unlock Full NCT07723963 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07723963 Rescue Dossier →